4.5 Article

Adult Outcome of Attention-Deficit/Hyperactivity Disorder: A Controlled 16-Year Follow-Up Study

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 73, Issue 7, Pages 941-950

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.11m07529

Keywords

-

Funding

  1. Elminda
  2. Janssen
  3. McNeil
  4. Shire
  5. Fundacion Dr Manuel Camelo A.C. in Monterrey, Mexico
  6. Abbott
  7. Alza
  8. AstraZeneca
  9. Boston University
  10. Bristol-Myers Squibb
  11. Celltech
  12. Cephalon
  13. Eli Lilly
  14. Esai
  15. Fundacion Areces (Spain)
  16. Forest
  17. Glaxo
  18. Gliatech
  19. Hastings Center
  20. Medice Pharmaceuticals (Germany)
  21. Merck
  22. MMC Pediatric
  23. National Alliance for Research on Schizophrenia and Depression
  24. National Institute on Drug Abuse
  25. National Institute of Child Health and Human Development
  26. National Institute of Mental Health
  27. Novartis
  28. Noven
  29. Neurosearch
  30. Organon
  31. Otsuka
  32. Pfizer
  33. Pharmacia
  34. Phase V Communications
  35. Physicians Academy
  36. Prechter Foundation
  37. Quantia Communications
  38. Reed Exhibitions
  39. Spanish Child Psychiatry Association
  40. Stanley Foundation
  41. UCB Pharma
  42. Veritas
  43. Wyeth
  44. Alcobra
  45. National Institutes of Health
  46. Lilly Foundation
  47. Pediatric Psychopharmacology Council Fund of the Massachusetts General Hospital, Boston
  48. New River

Ask authors/readers for more resources

Objective: To estimate the risks for psychopathology and functional impairments in adulthood among a longitudinal sample of youth with and without attention-deficit/hyperactivity disorder (ADHD) diagnosed in childhood. Method: This was a case-controlled, 16-year (15-19 years) prospective follow-up study of ADHD. 140 boys with and 120 without DSM-III-R ADHD were recruited from pediatric and psychiatric settings. The main outcome measures were structured diagnostic interviews and measures of psychosocial, educational, and neuropsychological functioning. Data were collected from 1988 to 2006. Results: At the 16-year follow-up, subjects with ADHD continued to significantly differ from controls in lifetime rates of antisocial, mood, anxiety, and addictive disorders, but with the exception of a higher interval prevalence of anxiety disorders (20% vs 8%; z = 2.32, P = .02) and smoking dependence (27% vs 11%; z = 2.30, P = .02), the incidence of individual disorders in the 6-year interval between the current and prior follow-up did not differ significantly from controls. At follow-up, the ADHD subjects compared with controls were significantly (P < .05) more impaired in psychosocial, educational, and neuropsychological functioning, differences that could not be accounted for by other active psychopathology. Conclusions: These long-term prospective findings provide further evidence for the high morbidity associated with ADHD across the life cycle, stressing the importance of early recognition of this disorder for prevention and early intervention strategies. These findings also indicate that, in adulthood, ADHD confers significant risks for impairment that cannot be accounted for by other psychopathology. J Clin Psychiatry 2012;73(7):941-950 (c) Copyright 2012 Physicians Postgraduate Press, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available